These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 23488770)

  • 1. Different glycosylation pattern of human IgG1 and IgG3 antibodies isolated from transiently as well as permanently transfected cell lines.
    Vestrheim AC; Moen A; Egge-Jacobsen W; Bratlie DB; Michaelsen TE
    Scand J Immunol; 2013 May; 77(5):419-28. PubMed ID: 23488770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural difference in the complement activation site of human IgG1 and IgG3.
    Michaelsen TE; Sandlie I; Bratlie DB; Sandin RH; Ihle O
    Scand J Immunol; 2009 Dec; 70(6):553-64. PubMed ID: 19906198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced sialylation of a human chimeric IgG1 variant produced in human and rodent cell lines.
    Mimura Y; Kelly RM; Unwin L; Albrecht S; Jefferis R; Goodall M; Mizukami Y; Mimura-Kimura Y; Matsumoto T; Ueoka H; Rudd PM
    J Immunol Methods; 2016 Jan; 428():30-6. PubMed ID: 26627984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human IgG1, IgG3, and IgG3 Hinge-Truncated Mutants Show Different Protection Capabilities against Meningococci Depending on the Target Antigen and Epitope Specificity.
    Giuntini S; Granoff DM; Beernink PT; Ihle O; Bratlie D; Michaelsen TE
    Clin Vaccine Immunol; 2016 Aug; 23(8):698-706. PubMed ID: 27307451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells.
    Wright A; Morrison SL
    J Immunol; 1998 Apr; 160(7):3393-402. PubMed ID: 9531299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region.
    Tao MH; Morrison SL
    J Immunol; 1989 Oct; 143(8):2595-601. PubMed ID: 2507634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities.
    Natsume A; In M; Takamura H; Nakagawa T; Shimizu Y; Kitajima K; Wakitani M; Ohta S; Satoh M; Shitara K; Niwa R
    Cancer Res; 2008 May; 68(10):3863-72. PubMed ID: 18483271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The N-linked oligosaccharide at Fc gamma RIIIa Asn-45: an inhibitory element for high Fc gamma RIIIa binding affinity to IgG glycoforms lacking core fucosylation.
    Shibata-Koyama M; Iida S; Okazaki A; Mori K; Kitajima-Miyama K; Saitou S; Kakita S; Kanda Y; Shitara K; Kato K; Satoh M
    Glycobiology; 2009 Feb; 19(2):126-34. PubMed ID: 18952826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C1q binding to chimeric monoclonal IgG3 antibodies consisting of mouse variable regions and human constant regions with shortened hinge containing 15 to 47 amino acids.
    Sandlie I; Aase A; Westby C; Michaelsen TE
    Eur J Immunol; 1989 Sep; 19(9):1599-603. PubMed ID: 2792180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell type-specific and site directed N-glycosylation pattern of FcγRIIIa.
    Zeck A; Pohlentz G; Schlothauer T; Peter-Katalinić J; Regula JT
    J Proteome Res; 2011 Jul; 10(7):3031-9. PubMed ID: 21561106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mutant human IgG molecule with only one C1q binding site can activate complement and induce lysis of target cells.
    Michaelsen TE; Thommesen JE; Ihle O; Gregers TF; Sandin RH; Brekke OH; Sandlie I
    Eur J Immunol; 2006 Jan; 36(1):129-38. PubMed ID: 16323243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysine 322 in the human IgG3 C(H)2 domain is crucial for antibody dependent complement activation.
    Thommesen JE; Michaelsen TE; Løset GÅ; Sandlie I; Brekke OH
    Mol Immunol; 2000 Nov; 37(16):995-1004. PubMed ID: 11395138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
    Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
    J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of complement by human IgG1 and human IgG3 antibodies against the human leucocyte antigen CD52.
    Redpath S; Michaelsen T; Sandlie I; Clark MR
    Immunology; 1998 Apr; 93(4):595-600. PubMed ID: 9659234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Affinity of the interaction between Fc gamma receptor type III (Fc gammaRIII) and monomeric human IgG subclasses. Role of Fc gammaRIII glycosylation.
    Galon J; Robertson MW; Galinha A; Mazières N; Spagnoli R; Fridman WH; Sautès C
    Eur J Immunol; 1997 Aug; 27(8):1928-32. PubMed ID: 9295028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of the hinge region length in binding of human IgG to human Fcgamma receptors.
    Redpath S; Michaelsen TE; Sandlie I; Clark MR
    Hum Immunol; 1998 Nov; 59(11):720-7. PubMed ID: 9796740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fc-Glycosylation in Human IgG1 and IgG3 Is Similar for Both Total and Anti-Red-Blood Cell Anti-K Antibodies.
    Sonneveld ME; Koeleman CAM; Plomp HR; Wuhrer M; van der Schoot CE; Vidarsson G
    Front Immunol; 2018; 9():129. PubMed ID: 29445378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The functional activity of Fc gamma RII and Fc gamma RIII on subsets of human lymphocytes.
    Hadley AG; Zupanska B; Kumpel BM; Leader KA
    Immunology; 1992 Jul; 76(3):446-51. PubMed ID: 1356095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering.
    Schuster M; Umana P; Ferrara C; Brünker P; Gerdes C; Waxenecker G; Wiederkum S; Schwager C; Loibner H; Himmler G; Mudde GC
    Cancer Res; 2005 Sep; 65(17):7934-41. PubMed ID: 16140965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural characterization of the Man5 glycoform of human IgG3 Fc.
    Shah IS; Lovell S; Mehzabeen N; Battaile KP; Tolbert TJ
    Mol Immunol; 2017 Dec; 92():28-37. PubMed ID: 29031045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.